ImmunityBio Inc (IBRX)

[axelvento]

ImmunityBio, Inc.- a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, increasing the total committed capital under the Agreement to $375 million. The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap.


https://immunitybio.com/immunitybio-strengthens-balance-sheet-with-100-million-of-financing-transactions-including-75-million-of-non-dilutive-financing-to-support-global-expansion-and-advancement-of-broader-immunotherapy-p/